Shares of Lonza Group climbed 2.9% in Swiss trade after Moderna (MRNA) reported positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus. The companies intend to manufacture the first batches of mRNA-1273 at Lonza U.S. in July 2020. Lonza shares have climbed 31% this year.
-Steve Goldstein; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
May 18, 2020 08:25 ET (12:25 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.